ArticleVaccine2009
Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.British journal of cancer · 2010Trial
- Review
- Regulatory T cell frequency in peripheral blood of women with advanced cervical Cancer including women living with HIV.BMC cancer · 2023Article
- Comparison of the inhibitory and stimulatory effects of Core and NS3 candidate HCV vaccines on the cellular immune response.American journal of clinical and experimental immunology · 2023Article
- Article
- Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Human gene therapy · 2018Article
- Therapeutic vaccines for high-risk HPV-associated diseases.Papillomavirus research (Amsterdam, Netherlands) · 2018Review
- Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.Cancer immunology, immunotherapy : CII · 2018Article
- Current state in the development of candidate therapeutic HPV vaccines.Expert review of vaccines · 2016Review
- Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models.Cancer immunology, immunotherapy : CII · 2015Review
- Therapeutic Vaccine Strategies against Human Papillomavirus.Vaccines · 2014Review
- Article
- Virus-like particles for the prevention of human papillomavirus-associated malignancies.Expert review of vaccines · 2013Review
- HPV infection: immunological aspects and their utility in future therapy.Infectious diseases in obstetrics and gynecology · 2013Review
- An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.PloS one · 2013Article
- Vaccination in the elderly.Microbial biotechnology · 2012Review
- Partial regulatory T cell depletion prior to schistosomiasis vaccination does not enhance the protection.PloS one · 2012Article
- Partial regulatory T cell depletion prior to acute feline immunodeficiency virus infection does not alter disease pathogenesis.PloS one · 2011Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Therapeutic human papillomavirus (HPV) vaccines targeting E6 and/or E7 antigens represent an opportunity to control HPV-associated lesions. We have previously generated several therapeutic DNA vaccines targeting HPV-16 E7 antigen and generated significant antitumor effects. Since regulatory T cells (Tregs) play an important role in suppressing immune responses against tumors by immunotherapy, such as DNA vaccines, we tested if the therapeutic effects of a DNA vaccine encoding E7 linked to heat shock protein 70 (Hsp70) can be improved by a strategy to deplete Tregs using a anti-CD25 monoclonal antibody (PC61) in vaccinated mice. We found that administration of PC61 prior to vaccination with E7/Hsp70 DNA was capable of generating higher levels of E7-specific CD8(+) T cells compared to the control antibody, leading to significantly improved therapeutic and long-term protective antitumor effects against an E7-expressing tumor, TC-1. Thus, a strategy to deplete CD4(+)CD25(+) Tregs in conjunction with therapeutic tumor antigen-specific DNA vaccine may represent a potentially promising approach to control tumor. The clinical implications of our study are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.